141 related articles for article (PubMed ID: 31407221)
1. Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.
Nassereddine H; Sannier A; Brosseau S; Rodier JM; Khalil A; Msika S; Danel C; Couvelard A; Théou-Anton N; Cazes A
Pathol Oncol Res; 2020 Oct; 26(4):2795-2800. PubMed ID: 31407221
[TBL] [Abstract][Full Text] [Related]
2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
3. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
5. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
6. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing in lung cancer: An initial experience from India.
Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
[TBL] [Abstract][Full Text] [Related]
9. [A Single Center, Retrospective Analysis of Prognosis in Non-small Cell Lung Cancer Patients with Peritoneal Carcinomatosis].
Cao B; Liu Y; Yin W; Li Q; Liang L
Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):143-150. PubMed ID: 30909993
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
11. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
[TBL] [Abstract][Full Text] [Related]
12. An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Eur J Cancer; 2020 Jun; 132():24-34. PubMed ID: 32325417
[TBL] [Abstract][Full Text] [Related]
13. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
14. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
15. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
17. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Alexander M; Pavlakis N; John T; O'Connell R; Kao S; Hughes BGM; Lee A; Hayes SA; Howell VM; Clarke SJ; Millward M; Burbury K; Solomon B; Itchins M
Lung Cancer; 2020 Apr; 142():34-40. PubMed ID: 32087434
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations.
Lee HW; Park YS; Park S; Lee CH
Sci Rep; 2020 Sep; 10(1):14933. PubMed ID: 32913267
[TBL] [Abstract][Full Text] [Related]
19. IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
Rodriguez EF; De Marchi F; Lokhandwala PM; Belchis D; Xian R; Gocke CD; Eshleman JR; Illei P; Li MT
Cancer Med; 2020 Jun; 9(12):4386-4394. PubMed ID: 32333643
[TBL] [Abstract][Full Text] [Related]
20. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
